|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
California Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing CaliforniaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
StemCells Inc.
| | | Phone: | (510) 456-4000 | Year Established: | 1988 | Employees: | 50 | Ticker: | STEM | Exchange: | NASDAQ | Main Contact: | Stewart Craig, Ph.D., Senior VP, Development & Operations | | Other Contacts: | Mohammad A. El-Kalay, Ph.D., VP, Process Development Naymisha Patel, VP, Quality Systems Joel Naor, M.D., M.B.A., M.Sc., VP, Clinical Development, Ophthalmology Allyson Gage, Ph.D., Senior Director of Clinical Development. Nicki Vasquez, Ph.D., VP, Program & Portfolio Management Ann Tsukamoto, Ph.D., Executive VP, Scientific & Strategic Alliances Nobuko Uchida, Ph.D., VP, Stem Cell Biology Maria Millan, MD, FACS, VP & Head of the Liver Program Dennise Dalma-Weiszhausz, Ph.D., VP, R&D Services Stephen Huhn, MD, FACS, FAAP, VP, CNS Clinical Research & CMO Ken Stratton, General Counsel Greg Schiffman, CFO & VP, Finance & Administration Eliseo Salinas, M.D., Executive VP, R&D Ian Massey, Ph.D., CEO
| | Company Description | StemCells, Inc. (formerly Cellular Transplants and CytoTherapeutics) is engaged in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery. The Company's lead therapeutic product candidate, HuCNS-SC(R) cells (purified human neural stem cells), is currently in development as a potential treatment for a broad range of central nervous system disorders. Clinical trials are currently underway in spinal cord injury and in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in children. The Company's HuCNS-SC cells are also in preclinical development for retinal disorders, such as age-related macular degeneration, and for Alzheimer's disease and Stroke. StemCells also markets stem cell research products, including media and reagents, under the SC Proven(R)brand, and is developing stem cell-based assay platforms for use in pharmaceutical research, drug discovery and drug development.
On Aug. 16, 2016, StemCells, Inc. and Microbot Medical, a private company organized under the laws of the State of Israel,announced a merger agreement, with plans to pursue the development of robotics based medical devices for treatment of cerebrospinal fluid and gastrointestinal disorders. | |
|
|
|